Skip to content
10-Q

Quarterly Report

Ibere Pharmaceuticals

0001410578-22-003339

← back to feed
Filed
Nov 14, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q3 2022 · Sep 30, 2022 −$612.8K
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$798.63K
Short Term Debt Q3 2022 · Sep 30, 2022 $0
Cash And Equivalents Q3 2022 · Sep 30, 2022 $4.45K
Cash And Equivalents Q3 2022 · Dec 31, 2021 $458.39K
Stockholders Equity Q3 2022 · Sep 30, 2022 −$5.83M
Stockholders Equity Q3 2022 · Jun 30, 2022 −$5.89M
Stockholders Equity Q3 2022 · Mar 31, 2022 −$7.28M
Stockholders Equity Q3 2022 · Dec 31, 2021 −$10.85M
Stockholders Equity restated Q3 2022 · Sep 30, 2021 −$11.19M
Stockholders Equity restated Q3 2022 · Jun 30, 2021 −$12.92M
Stockholders Equity restated Q3 2022 · Mar 31, 2021 −$12.8M
Stockholders Equity Q3 2022 · Dec 31, 2020 $19.24K
Current Liabilities Q3 2022 · Sep 30, 2022 $469K
Current Liabilities Q3 2022 · Dec 31, 2021 $372.44K
Total Liabilities Q3 2022 · Sep 30, 2022 $5.95M
Total Liabilities Q3 2022 · Dec 31, 2021 $11.54M
Current Assets Q3 2022 · Sep 30, 2022 $113.2K
Current Assets Q3 2022 · Dec 31, 2021 $693.39K
Total Assets Q3 2022 · Sep 30, 2022 $138.96M
Total Assets Q3 2022 · Dec 31, 2021 $138.71M
Net Income Q3 2022 · Sep 30, 2022 $789.82K
Net Income Q3 2022 · Sep 30, 2022 $5.84M
Net Income Q3 2022 · Jun 30, 2022 $1.47M
Net Income Q3 2022 · Mar 31, 2022 $3.57M
Net Income Q3 2022 · Sep 30, 2021 $1.73M
Net Income Q3 2022 · Sep 30, 2021 $1.21M
Net Income Q3 2022 · Jun 30, 2021 −$112.27K
Net Income Q3 2022 · Mar 31, 2021 −$405.7K
Operating Income Q3 2022 · Sep 30, 2022 −$233.6K
Operating Income Q3 2022 · Sep 30, 2022 −$676.75K
Operating Income Q3 2022 · Sep 30, 2021 −$315.5K
Operating Income Q3 2022 · Sep 30, 2021 −$643.73K